全文获取类型
收费全文 | 28600篇 |
免费 | 2459篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 187篇 |
儿科学 | 1113篇 |
妇产科学 | 836篇 |
基础医学 | 4163篇 |
口腔科学 | 463篇 |
临床医学 | 3724篇 |
内科学 | 5149篇 |
皮肤病学 | 349篇 |
神经病学 | 3229篇 |
特种医学 | 599篇 |
外科学 | 2736篇 |
综合类 | 421篇 |
一般理论 | 50篇 |
预防医学 | 3643篇 |
眼科学 | 497篇 |
药学 | 1918篇 |
中国医学 | 46篇 |
肿瘤学 | 1992篇 |
出版年
2023年 | 245篇 |
2022年 | 120篇 |
2021年 | 580篇 |
2020年 | 437篇 |
2019年 | 655篇 |
2018年 | 743篇 |
2017年 | 544篇 |
2016年 | 607篇 |
2015年 | 666篇 |
2014年 | 941篇 |
2013年 | 1365篇 |
2012年 | 1943篇 |
2011年 | 2033篇 |
2010年 | 1080篇 |
2009年 | 1036篇 |
2008年 | 1622篇 |
2007年 | 1851篇 |
2006年 | 1830篇 |
2005年 | 1674篇 |
2004年 | 1636篇 |
2003年 | 1488篇 |
2002年 | 1419篇 |
2001年 | 419篇 |
2000年 | 381篇 |
1999年 | 327篇 |
1998年 | 311篇 |
1997年 | 254篇 |
1996年 | 213篇 |
1995年 | 191篇 |
1994年 | 169篇 |
1993年 | 191篇 |
1992年 | 232篇 |
1991年 | 228篇 |
1990年 | 209篇 |
1989年 | 223篇 |
1988年 | 199篇 |
1987年 | 243篇 |
1986年 | 184篇 |
1985年 | 191篇 |
1984年 | 169篇 |
1983年 | 167篇 |
1982年 | 121篇 |
1981年 | 119篇 |
1980年 | 124篇 |
1979年 | 116篇 |
1978年 | 113篇 |
1977年 | 96篇 |
1976年 | 107篇 |
1974年 | 111篇 |
1973年 | 122篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Aliyah Hussein Kiran Sran Imran Ali Janine Woellner Helen Wilcox Stephen D. Marks Helen Jones Chris Callaghan 《Pediatric transplantation》2020,24(4)
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
10.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献